Format

Send to

Choose Destination
Nat Rev Neurosci. 2017 Nov 16;18(12):753-769. doi: 10.1038/nrn.2017.136.

Regenerating CNS myelin - from mechanisms to experimental medicines.

Author information

1
Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Clifford Allbutt Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AH, UK.
2
MRC Centre for Regenerative Medicine, Edinburgh bioQuarter, University of Edinburgh, Edinburgh, EH16 4UU, UK.

Abstract

Although the core concept of remyelination - based on the activation, migration, proliferation and differentiation of CNS progenitors - has not changed over the past 20 years, our understanding of the detailed mechanisms that underlie this process has developed considerably. We can now decorate the central events of remyelination with a host of pathways, molecules, mediators and cells, revealing a complex and precisely orchestrated process. These advances have led to recent drug-based and cell-based clinical trials for myelin diseases and have opened up hitherto unrecognized opportunities for drug-based approaches to therapeutically enhance remyelination.

PMID:
29142295
DOI:
10.1038/nrn.2017.136
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center